Loading…
Results show significant improvement over a leading on-market reference antihistamine product.
Gelteq Limited (XNAS: GELS) announced on November 24, 2025, positive preclinical results demonstrating enhanced bioavailability using its proprietary gel-based drug delivery platform. The results indicate a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax).
The company's gel-based platform showed promising outcomes in preclinical trials, highlighting its potential to improve drug delivery efficiency. Gelteq's free float stands at 5,455,600 shares, with 10,711,100 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.